Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 45% unadjusted Improvement Relative Risk ICU admission 58% unadjusted Hospitalization 5% primary, unadjusted Mortality (b) -17% unadjusted ICU admission (b) 9% unadjusted Hospitalization (b) 28% unadjusted Cooper et al. Bamlanivimab/e.. for COVID-19 EARLY Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 10,961 patients in the USA Lower ICU admission with bamlanivimab/etesevimab (not stat. sig., p=0.33) Cooper et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512 Favors bamlanivimab/e.. Favors control
Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study
Cooper et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512
Cooper et al., Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512
Oct 2021   Source   PDF  
  All Studies   Meta
Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with bamlanivimab, bamlanivimab/etesevimab, and casirivimab/imdevimab. There was significantly lower hospitalization with casirivimab/imdevimab compared to bamlanivimab or bamlanivimab/etesevimab. PSM and multivariate analysis is only provided for all treatments combined.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan]. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 45.3% lower, RR 0.55, p = 1.00, treatment 1 of 473 (0.2%), control 33 of 8,534 (0.4%), NNT 571, unadjusted, bamlanivimab-etesevimab.
risk of ICU admission, 57.5% lower, RR 0.42, p = 0.33, treatment 2 of 473 (0.4%), control 85 of 8,534 (1.0%), NNT 174, unadjusted, bamlanivimab-etesevimab.
risk of hospitalization, 5.0% lower, RR 0.95, p = 0.86, treatment 37 of 473 (7.8%), control 703 of 8,534 (8.2%), NNT 241, unadjusted, bamlanivimab-etesevimab, primary outcome.
risk of death, 17.2% higher, RR 1.17, p = 0.59, treatment 11 of 2,427 (0.5%), control 33 of 8,534 (0.4%), unadjusted, bamlanivimab.
risk of ICU admission, 9.0% lower, RR 0.91, p = 0.81, treatment 22 of 2,427 (0.9%), control 85 of 8,534 (1.0%), NNT 1117, unadjusted, bamlanivimab.
risk of hospitalization, 28.0% lower, RR 0.72, p < 0.001, treatment 144 of 2,427 (5.9%), control 703 of 8,534 (8.2%), NNT 43, unadjusted, bamlanivimab.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cooper et al., 8 Oct 2021, retrospective, USA, peer-reviewed, 9 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study us cr ip t Nguyen3, James M. Musser2,3, Howard J. Huang4, Michael G. Liebl1,* 1 Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA 2 Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist M 3 an USA Research Institute, Houston, Texas, USA ce Houston, TX, USA d Division of Pulmonology, Pulmonary, Critical Care & Sleep Medicine, Houston Methodist Hospital, pt e 4 Ac *Corresponding author: Michael G. Liebl, PharmD, BCPS; 7550 Greenbriar Dr. RB6-126, Houston, TX, USA 77030; Ph: 346.356.1757; Email: Alternate corresponding author: © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (, which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact Megan H. Cooper1, Paul A. Christensen2, Eric Salazar2, Katherine K. Perez1,2, Edward A. Graviss3, Duc Megan H. Cooper, PharmD; 6565 Fannin St, DB1-09, Houston, TX, USA 77030; Ph: 713-441-7055; Email: Summary: We assessed the outcomes of 2,879 SARS-CoV-2-positive patients transfused with one of t cohort. We found that administration of mAbs significantly reduced 28-day hospitalizations and us cr ip mortality. Abstract Background: SARS-CoV-2 continues to spread globally and cause significant morbidity and mortality. an Anti-spike protein monoclonal antibody (mAb) therapy has been shown to prevent progression to severe COVID-19 disease. The objective of this study was to report the outcomes of high-risk, SARS- M CoV-2-positive patients infused with one of the three mAb available through FDA emergency use d authorization (EUA). pt e Methods: A total of 4,328 SARS-CoV-2-positive patients that satisfied EUA criteria for eligibility for receiving mAb therapy were infused with bamlanivimab or combination therapies bamlanivimab- ce etesevimab or casirivimab-imdevimab from November 22, 2020, to May 31, 2021, at six infusion clinics and multiple emergency departments within the eight Houston Methodist Hospitals in Ac Houston, Texas. The primary outcome of hospital admission within 14- and 28-days post-infusion was assessed relative to a propensity-score matched cohort, matched based on age, race/ethnicity, median income by zip code, body mass index, comorbidities, and positive PCR date. Secondary outcomes included ICU admission and mortality. Results: A total of 2,879 infused patients and matched controls were included in the analysis, including 1,718 patients infused with bamlanivimab, 346 patients infused with bamlanivimab- 2 three available monoclonal antibody..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop